Solasia Pharma Licenses Episil to GeneScience for Greater China Region
CompanyDeals

Solasia Pharma Licenses Episil to GeneScience for Greater China Region

Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines
CompanyDeals

Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines

GSK's Nucala Receives New Indication Approval in China for CRSwNP
CompanyDrug

GSK’s Nucala Receives New Indication Approval in China for CRSwNP

China's Healthcare Bureaus Remove Drug Quantity Limits to Enhance NRDL Access
Policy / Regulatory

China’s Healthcare Bureaus Remove Drug Quantity Limits to Enhance NRDL Access

Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau
CompanyDeals

Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau

Shengwei Kunteng Raises RMB 200 Million in Series A Financing for POCT Development
CompanyDeals

Shengwei Kunteng Raises RMB 200 Million in Series A Financing for POCT Development

Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round
CompanyDeals

Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round

Aosaikang's Generic Livtencity Accepted for Review by China's NMPA
CompanyDrug

Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA

Sinobioway Biomedicine Partners with Happy Life Tech for Clinical Trial Services
CompanyDeals

Sinobioway Medicine Partners with Happy Life Tech for Clinical Trial Services

Balance Medtech's Interventional Pulmonary Valve Receives Fast-Track Designation from NMPA
CompanyMedical Device

Balance Medtech’s Interventional Pulmonary Valve Receives Fast-Track Designation from NMPA

MicuRx Pharmaceuticals' MRX-5 Receives NMPA Approval for NTM Infections Clinical Study
CompanyDrug

MicuRx Pharmaceuticals’ MRX-5 Receives NMPA Approval for NTM Infections Clinical Study

Huahai Pharmaceutical's HB0028 and HB002.1T Cleared for Clinical Study by NMPA
CompanyDrug

Huahai Pharmaceutical’s HB0028 and HB002.1T Cleared for Clinical Study by NMPA